These genes serve as key metabolic markers distinguishing CRC subtypes based on molecular heterogeneity and prognosis.<h4>Conclusion</h4>PDE2A and CKMT2 were identified as critical metabolic biomarkers associated with distinct CRC subtypes and TME compositions. This evidence concerns the gene CKMT2 and colorectal carcinoma.